[Active life termination in children aged 1-12 years].
Marije A Brouwer1, Els L M Maeckelberghe1, A A E Verhagen1,2
1UMCG, afd. Kindergeneeskunde, Groningen.
Nederlands Tijdschrift Voor Geneeskunde
|February 6, 2024
Summary
Active termination of life for children aged 1-12 facing unbearable suffering will be regulated in 2024. This article explores physician responses to such requests when other relief options are insufficient.
Area of Science:
- Pediatric Ethics
- Medical Law
- End-of-Life Care
Context:
- Upcoming regulation of active termination of life for children aged 1-12 years in 2024.
- Focus on cases of unbearable suffering where other palliative options are exhausted.
Purpose:
- To discuss the ethical and practical considerations of active termination of life in pediatric patients.
- To outline physician responses to requests for active termination of life in children.
Summary:
- Examines the legal and ethical framework for active termination of life in children (1-12 years) facing extreme suffering.
- Details how requests for pediatric active termination of life may arise and guides physician responses.
- Highlights the importance of comprehensive care and ethical decision-making in pediatric end-of-life scenarios.
Impact:
- Provides guidance for healthcare professionals navigating complex end-of-life decisions in pediatric care.
- Contributes to the discourse on legal and ethical standards for pediatric termination of life.
- Informs policy development and clinical practice regarding pediatric palliative and end-of-life care.
More Related Videos
11:27A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn
Published on: April 7, 2023
6.3K
06:49Orthotopic Ovarian Transplantation Procedures to Investigate the Life- and Health-span Influence of Ovarian Senescence in Female Mice
Published on: February 12, 2018
10.9K
Related Concept Videos
01:07Teratogenicity
2.5K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.5K
01:30Attention-Deficit/Hyperactivity Disorder
68
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
68